Approval Date: 9/23/2008
Principal Investigator: David Decker, MD
Eligibility:
- Women or men with Stage IV breast cancer, which is bone-predominant
- Patient may have had 0 or 1 prior chemotherapy regimens for metastatic disease
- Patients who are ER + and/or PgR + must have progressed on at least one hormonal therapy in the metastatic setting
- Patient must consent to serum and whole blood specimen submission
Contact Person:
Royal Oak
248-551-7695
Troy
248-964-0606
Status of Clinical Trial:
open and enrolling
